Cargando…

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin

OBJECTIVES: This is a prospective study evaluating NEPA in patients with breast cancer (the NEPA group), who received (neo)adjuvant AC chemotherapy (consisting of doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2)). The primary objectives were to assess the efficacy and safety of NEPA in contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Winnie, Lau, Thomas KH, Kwok, Carol CH, Lai, Kwai T, Chan, Vicky TC, Li, Leung, Chan, Vivian, Wong, Ashley, Soo, Winnie MT, Yeung, Eva WM, Wong, Kam H, Tang, Nelson LS, Suen, Joyce JS, Mo, Frankie KF
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304103/ https://www.ncbi.nlm.nih.gov/pubmed/31996363 http://dx.doi.org/10.1136/bmjspcare-2019-002037

Ejemplares similares

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies
por: Yeo, Winnie, et al.
Publicado: (2021)

A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
por: Yeo, Winnie, et al.
Publicado: (2020)

Quality of Life Associated with Nausea and Vomiting from Anthracycline‐Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
por: Yeo, Winnie, et al.
Publicado: (2021)

Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
por: Yeo, Winnie, et al.
Publicado: (2020)

Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy
por: Yeo, Winnie, et al.
Publicado: (2018)

Imperfect protection: NEPA at 35 years.
por: Black, Harvey
Publicado: (2004)

Immunoglobulin-Induced Aseptic Meningitis in Juvenile Dermatomyositis: A Case Report
por: Chan, Oi Man, et al.
Publicado: (2022)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
por: Caputo, Roberta, et al.
Publicado: (2020)

Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
por: Li, Leung, et al.
Publicado: (2017)

Case Report: Multiple autoimmune syndrome (MAS)—An unusual combination
por: Kwong, Elaine Yi Lee, et al.
Publicado: (2022)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Paradoxical hypertension and salt wasting in Type II Bartter syndrome
por: Chan, Winnie Kwai-yu, et al.
Publicado: (2012)

Did the pandemic virus A(H1N1)PDM09 interfere other respiratory viruses? Evidence from the subtropical city Hong Kong
por: Yang, L, et al.
Publicado: (2015)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

Increased number of structured diabetes education attendance was not associated with the improvement in patient-reported health-related quality of life: results from Patient Empowerment Programme (PEP)
por: Wong, Carlos K.H., et al.
Publicado: (2015)

Evaluation of simulation-based ultrasound course for pediatricians: a starting point for future training curriculum
por: Kuok, Chon In, et al.
Publicado: (2021)

International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study
por: Chan, Stephen L., et al.
Publicado: (2014)

Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma
por: Chan, Anthony W. H., et al.
Publicado: (2015)

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
por: Yeo, Winnie, et al.
Publicado: (2015)

A chromosomal analysis of Nepa cinerea Linnaeus, 1758 and Ranatra linearis (Linnaeus, 1758) (Heteroptera, Nepidae)
por: Angus, Robert B., et al.
Publicado: (2017)

Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
por: Restelli, Umberto, et al.
Publicado: (2017)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
por: Vaswani, Bharat, et al.
Publicado: (2021)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Megapneumonia Coinfection: pneumococcus, Mycoplasma pneumoniae, and Metapneumovirus
por: Hon, Kam Lun, et al.
Publicado: (2012)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Cyclophosphamide/doxorubicin: Prolongation of SARS-CoV-2 infection: case report
Publicado: (2021)

Rare Case of Reversible Pulmonary Arterial Hypertension Secondary to Cyclophosphamide and Doxorubicin Chemotherapy
por: Javed, Aneeqa, et al.
Publicado: (2022)

Correction: Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
Publicado: (2017)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

Association between Auricular Signals and the Risk Factors of Metabolic Syndrome
por: Suen, Lorna Kwai Ping, et al.
Publicado: (2017)

Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma
por: Ma, Brigette, et al.
Publicado: (2018)

NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022)

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
por: Ferguson, J. E., et al.
Publicado: (1993)

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2016)

Increasing pacemaker lead impedance and pacing threshold after initiation of chemotherapy with doxorubicin and cyclophosphamide
por: Varela, Daniel L., et al.
Publicado: (2022)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m687skvj2ehs2q1n9jc7bm3ep3